U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H15NO2
Molecular Weight 277.3179
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEACETYLBISACODYL

SMILES

c1ccnc(c1)C(c2ccc(cc2)O)c3ccc(cc3)O

InChI

InChIKey=LJROKJGQSPMTKB-UHFFFAOYSA-N
InChI=1S/C18H15NO2/c20-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(21)11-7-14/h1-12,18,20-21H

HIDE SMILES / InChI

Molecular Formula C18H15NO2
Molecular Weight 277.3179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PREPOPIK

Approved Use

PREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Launch Date

1.34231045E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.3 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21.3 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
209 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
275 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
7.4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Analytical control of a pharmaceutical formulation of sodium picosulfate by capillary zone electrophoresis.
2001 Feb 10
Investigation of the effects of YM-31636, a novel 5-HT3 receptor agonist, on defecation in normal and constipated ferrets.
2001 Jul 20
Screening procedure for detection of stimulant laxatives and/or their metabolites in human urine using gas chromatography-mass spectrometry after enzymatic cleavage of conjugates and extractive methylation.
2005 Apr
[Distigmine bromide improves chronic intestinal pseudo-obstruction in a case of MELAS].
2007 Apr
Interaction between Shaoyao-Gancao-Tang and a laxative with respect to alteration of paeoniflorin metabolism by intestinal bacteria in rats.
2007 Aug
Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.
2007 Dec 3
Comparison of colon-cleansing methods in preparation for colonoscopy--comparative efficacy of solutions of mannitol, sodium picosulfate and monobasic and dibasic sodium phosphates.
2008
Changes of intestinal mucosal and plasma PYY in a diarrhea model rat and influence of loperamide as the treatment agent for diarrhea.
2008 Sep
[Optimization of perioperative management in laparoscopic hernioplasty].
2008 Sep
A multicentre, observational study of sodium picosulfate and magnesium citrate as a precolonoscopy bowel preparation.
2009 Oct
A review of laxative therapies for treatment of chronic constipation in older adults.
2010 Dec
Patents

Sample Use Guides

PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration: Oral
In Vitro Use Guide
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:55:43 UTC 2021
Edited
by admin
on Sat Jun 26 08:55:43 UTC 2021
Record UNII
R09078E41Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEACETYLBISACODYL
Common Name English
LA 96
Code English
BHPM
Common Name English
LA-96
Code English
BIS(4-HYDROXYPHENYL)(2-PYRIDYL)METHANE
Systematic Name English
DDPM
Common Name English
PHENOL, 4,4'-(2-PYRIDINYLMETHYLENE)BIS-
Systematic Name English
BIS-(P-HYDROXYPHENYL)PYRIDYL-2-METHANE
Common Name English
BISACODYL DIPHENOL
Common Name English
BISACODYL RELATED COMPOUND A
USP   USP-RS  
Common Name English
BISACODYL RELATED COMPOUND A [USP]
Common Name English
4,4'-(2-PYRIDINYLMETHYLENE)BISPHENOL
Systematic Name English
SODIUM PICOSULFATE SPECIFIED IMPURITY B [EP]
Common Name English
BISACODYL RELATED COMPOUND A [USP-RS]
Common Name English
BISACODYL IMPURITY A [EP]
Common Name English
DIHYDROXYDIPHENYL-PYRIDYL METHANE
Systematic Name English
4,4'-(2-PYRIDYLMETHYLENE)DIPHENOL
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000175812
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
Code System Code Type Description
USP_CATALOG
1074030
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB14232
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
EPA CompTox
603-41-8
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
PUBCHEM
69046
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
RXCUI
1872905
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
CAS
603-41-8
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
FDA UNII
R09078E41Y
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
ECHA (EC/EINECS)
210-039-7
Created by admin on Sat Jun 26 08:55:43 UTC 2021 , Edited by admin on Sat Jun 26 08:55:43 UTC 2021
PRIMARY
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (TLC)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY